October 15, 2018 | Aurealis Therapeutics

Aurealis Therapeutics Raises CHF 8 Million to Complete Phase 2 Clinical Studies in Chronic Wounds and Accelerate Oncology Program

Aurealis Therapeutics submits Clinical Trial Application for AUP-16 Phase 1 DFU study

Aurealis Therapeutics, a private biopharmaceutical company developing novel three-in-one combination biologics for chronic non-healing wounds and cancer announced today the successful submission of its first Clinical Trial Application (CTA) to the German Health Authority Paul-Ehrlich-Institute (PEI) for the lead development candidate AUP1602-C to be studied in a first-in-human phase 1-2A clinical study as treatment of […]

Baarerstrasse 21, CH-6300

Zug, Switzerland

Microkatu 1, FI-70210

Kuopio, Finland

Join our newsletter:

This information will only be used to send you our newsletter. You can unsubscribe at any moment.

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.

Cookie	Duration	Description
cookielawinfo-checbox-analytics	11 months	This cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checbox-functional	11 months	The cookie is to record the user consent for the cookies in the category "Functional".
cookielawinfo-checbox-others	11 months	This cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-necessary	11 months	This cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance	11 months	This cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
wordpress_[hash]	30 days	Its use is limited to the Administration Screen area
wordpress_logged_in_[hash]	30 days	Indicates when you’re logged in, and who you are, for most interface use.
wp-settings-{time}-[UID]	30 days	This is used to customize your view of admin interface, and possibly also the main site interface

Functional

Performance

Analytics

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.

Cookie	Duration	Description
_ga	2 years	Used to distinguish users.
_gac_aurealis	90 days	Contains campaign related information for the user.
_gat	1 minute	Used to throttle request rate. If Google Analytics is deployed via Google Tag Manager, this cookie will be named `_dc_gtm_<property-id>`.
_gid	24 hours	Used to distinguish users.
AMP_TOKEN	30 seconds to 1 year	Contains a token that can be used to retrieve a Client ID from AMP Client ID service.

Others

Day: October 15, 2018

Aurealis Therapeutics submits Clinical Trial Application for AUP-16 Phase 1 DFU study

Join our newsletter: